

OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2022-01-11 09:08:40

| | |
|--|-----------------------------------|
| Name of disease (or topic) for which you are a designated OIE Reference Laboratory: | Swine influenza |
| Address of laboratory: | Via Bianchi 9 25124 Brescia ITALY |
| Tel.: | +39 (0)52129.37.33 |
| Fax: | |
| E-mail address: | chiara.chiapponi@izsler.it |
| Website: | |
| Name (including Title) of Head of Laboratory (Responsible Official): | Dr. Piero Frazzi |
| Name (including Title and Position) of OIE Reference Expert: | Chiara Chiapponi |
| Which of the following defines your laboratory? Check all that apply: | Governmental |

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

| Diagnostic Test | Indicated in OIE Manual (Yes/No) | Total number of test performed last year | |
|---------------------------|----------------------------------|--|-----------------|
| | | Nationally | Internationally |
| Indirect diagnostic tests | | Nationally | Internationally |
| HI | yes | 12156 | 5045 |
| ELISA | yes | 296 | 0 |
| Direct diagnostic tests | | Nationally | Internationally |
| RT-PCR- M gene | yes | 2680 | 5 |
| cell culture inoculation | yes | 215 | 1 |
| eggs inoculation | yes | 44 | 0 |
| multiplex RT-PCR | yes | 202 | 1 |
| NGS sequencing | no | 88 | 66 |

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

| Type of reagent available | Related diagnostic test | Produced/ provide | Amount supplied nationally (ml, mg) | Amount supplied internationally (ml, mg) | No. of recipient OIE Member Countries | Region of recipients |
|---|-------------------------------|-------------------|-------------------------------------|--|---------------------------------------|--|
| SWINE INFLUENZA ANTIGEN H1N2 | HI TEST | PRODUCED/PROVIDED | 80 | NONE | 1 | <input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East |
| SWINE INFLUENZA ANTIGEN H3N2 | HI TEST | PRODUCED/PROVIDED | 80 | NONE | 1 | <input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East |
| SWINE INFLUENZA ANTIGEN H1N1pdm09 | HI TEST | PRODUCED/PROVIDED | 60 | NONE | 1 | <input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East |
| HYPERIMMUNE SERUM H1N1pdm09 | HI TEST | PRODUCED/PROVIDED | 1 | NONE | 1 | <input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East |
| 26 SWINE INFLUENZA ANTIGENS (H1N1, H1N2, H13N2, H1N1pdm09) LIVE STRAINS | HI ANTIGENIC CHARACTERIZATION | PRODUCED/PROVIDED | NONE | 1ML/EACH | 1 | <input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East |

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

| Name of OIE Member Country seeking assistance | Date (month) | No. samples received for provision of diagnostic support | No. samples received for provision of confirmatory diagnoses |
|---|--------------|--|--|
| CYPRUS | April | 361 | none |
| CYPRUS | May | 281 | none |
| CYPRUS | June | 426 | none |
| CYPRUS | July | 164 | none |
| CYPRUS | September | 256 | none |
| GREECE | April | 877 | none |
| GREECE | May | 272 | none |
| GREECE | June | 649 | none |
| GREECE | July | 381 | none |
| GREECE | September | 512 | none |
| GREECE | October | 302 | none |
| GREECE | November | 436 | none |
| GREECE | December | 132 | none |
| MALTA | April | 1 | none |

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

No

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

| Title of the study | Duration | Purpose of the study | Partners (Institutions) | OIE Member Countries involved other than your country |
|---|-----------|--|--|---|
| Understanding the dynamics and evolution of swine influenza viruses in Europe: relevance for improved intervention and sustainable pig production (PIGIE) | 2021-2024 | ICRAD Co-Funded Project: Research Area 1: Improved understanding of epidemic and emerging infectious animal diseases | French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Animal and Plant Health Agency (APHA), Friedrich-Loeffler-Institut (FLI), University of Copenhagen (UCPH), Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER), Universitat Autònoma de Barcelona (UAB) | DENMARK FRANCE GERMANY SPAIN UNITED KINGDOM |
| International swine Influenza Network | annual | European Network on swine Influenza | FLI, Riems, Germany; DTU, Copenhagen, Denmark; UAB, Barcelona, Spain; ANSES, Ploufragan, France; IZSve, Padua, Italy; IZSLER, Brescia, Italy; APHA, Weybridge, UK; Warsaw University, Warsaw, Poland; CEVA, Libourne, France | DENMARK FRANCE POLAND SPAIN UNITED KINGDOM |
| Swine influenza data for OFFLU contribution to WHO vaccine composition meeting | annual | To share animal influenza data with WHO in order to assist with selection of the most appropriate viruses for human vaccines, which can include animal viruses that present a potential to emerge into pandemic threats. | OFFLU Partners | |

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

Viral strains are isolated for genetic and antigenic characterization. Origin and date of sampling are collected

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

Sequencing data, origin and date of sampling (OFFLU-VCM),

**13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 2

Genetic Variability among Swine Influenza Viruses in Italy: Data Analysis of the Period 2017-2020

Chiara Chiapponi, Alice Prospero, Ana Moreno, Laura Baioni, Silvia Faccini, Roberta Manfredi, Irene Zanni, Valentina Gabbi, Irene Calanchi, Alice Fusaro, Maria Serena Beato, Lara Cavicchio, Camilla Torreggiani, Giovanni Loris Alborali and Andrea Luppi *Viruses* 2022, 14(1), 47; <https://doi.org/10.3390/v14010047> - 28 Dec 2021

Identification and Characterization of Swine Influenza Virus H1N1 Variants Generated in Vaccinated and Nonvaccinated, Challenged Pigs.

López-Valiñas Á, Sisteré-Oró M, López-Serrano S, Baioni L, Darji A, Chiapponi C, Segalés J, Ganges L, Núñez JI. *Viruses*. 2021 Oct 16;13(10):2087. doi: 10.3390/v13102087.

b) International conferences: 0

c) National conferences: 4

DYNAMIC EVOLUTION OF H1 SWINE VIRUSES: WHAT CAN WE EXPECT IN THE NEAR FUTURE?

A. Moreno, G. Alborali, L. Baioni, S. Faccini, A. Luppi, A. Prospero, C. Rosignoli, C. Salogni, S. Canziani, S. Salvato, T. Trogu, C. Chiapponi. 5TH NATIONAL CONGRESS OF THE ITALIAN SOCIETY FOR VIROLOGY-2021
CHARACTERIZATION OF INFLUENZA A VIRUSES ISOLATED DURING SWINE INFLUENZA'S OUTBREAKS IN ITALY, 2017-2020. CHIAPPONI C., PROSPERI A., MORENO A., FACCINI S., ALBORALI G.L., BAIONI L., GABBI V., MANFREDI R., TORREGGIANI C., LUPPI A. XLVI SIPAS annual Meeting (Verona, Italy, 2021)

FLU SCREENING IN TEN SWINE FARMS LOCATED IN LOMBARDY. GUADAGNINI G., PONZONI D., OTTOLINI F., COSSETTINI C., ZANNI I., CHIAPPONI C., PROSPERI A., LUPPI A. XLVI SIPAS annual Meeting (Verona, Italy, 2021)

ECOLOGY AND EVOLUTION OF SwIAV: THE IMPORTANCE OF A DYNAMIC GENOTYPING APPROACH. PROSPERI A., CHIAPPONI C., ROSIGNOLI C., MORENO A., FACCINI S., ALBORALI L., BAIONI L., GABBI V., CALANCHI I., MANFREDI R., LUPPI A. National Congress S.I.Di.L.V. Italy 2021

d) Other:

(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

| Quality management system adopted | Certificate scan (PDF, JPG, PNG format) |
|-----------------------------------|---|
| EN ISO/IEC 17025:2018 | Accreditation_certificate_Lab0148L.pdf |

16. Is your quality management system accredited?

Yes

| Test for which your laboratory is accredited | Accreditation body |
|--|--------------------|
| Matrix (M) gene PCR | ILAC-MRA_Accredia |

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

| Purpose of the proficiency tests: ¹ | Role of your Reference Laboratory (organiser/ participant) | No. participants | Participating OIE Ref. Labs/ organising OIE Ref. Lab. |
|--|--|------------------|--|
| Detection of influenza A virus by molecular test | participant | 18 | OIE Reference laboratory for avian Influenza Padua Italy |

¹ validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

| Title of the project or contract | Scope | Name(s) of relevant OIE Reference Laboratories |
|---|---|--|
| Understanding the dynamics and evolution of swine influenza viruses in Europe: relevance for improved intervention and sustainable pig production-PIGIE (ICRAD) | ICRAD Research Area 1: Improved understanding of epidemic and emerging infectious animal diseases | Animal and Plant Health Agency (APHA) |

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report:

The COVID-19 pandemic has impacted international laboratory activities in terms of participation to meetings and exchange of personnel.